Loading clinical trials...
Loading clinical trials...
A Phase 3, Double-blind, Randomized, Placebo-controlled Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease
Conditions
Interventions
AA4500
Placebo
Locations
34
United States
Urology Centers of Alabama, PC
Homewood, Alabama, United States
HOPE Research Institute, LLC
Phoenix, Arizona, United States
Urology Associates Medical Group
Burbank, California, United States
California Professional Research
Newport Beach, California, United States
San Diego Sexual Medicine
San Diego, California, United States
Grove Hill Clinical Research, Grove Hill Medical Center
New Britain, Connecticut, United States
Start Date
September 1, 2010
Primary Completion Date
April 1, 2012
Completion Date
April 1, 2012
Last Updated
October 5, 2017
Lead Sponsor
Endo Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions